1
/
of
1
store-traders-com
Stocks & Commodities V. 36:07 (3639): Biotech ETFs: A Slice Of Medical Science by Leslie N. Masonson
Stocks & Commodities V. 36:07 (3639): Biotech ETFs: A Slice Of Medical Science by Leslie N. Masonson
Regular price
$2.95 USD
Regular price
Sale price
$2.95 USD
Quantity
Couldn't load pickup availability
Biotech ETFs: A Slice Of Medical Science by Leslie N. Masonson
Are you interested in learning more about using exchange traded funds (ETFs) in your trading? Leslie N. Masonson, an active ETF trader, is president of Cash Management Resources, a financial consulting firm that focuses on ETF strategies. He is the author of BuyDont Hold: Investing With ETFs Using Relative Strength To Increase Returns With Less Risk; and All About Market Timing, as well as Day Trading On The Edge. His website is www.buydonthold.com, where he writes a weekly blog. To submit topics for future columns, reach him at lesmasonson@yahoo.com.
Buy & holders of biotech stocks have been well rewarded over the last 10 years; however, they needed an iron stomach to withstand the big drawdowns during corrections and bear market declines. Any major earnings miss or FDA disapprovals can easily result in a 25% decline or more in the stock price. That is why many investors select a biotech mutual fund or ETF to spread out the risk ...
Are you interested in learning more about using exchange traded funds (ETFs) in your trading? Leslie N. Masonson, an active ETF trader, is president of Cash Management Resources, a financial consulting firm that focuses on ETF strategies. He is the author of BuyDont Hold: Investing With ETFs Using Relative Strength To Increase Returns With Less Risk; and All About Market Timing, as well as Day Trading On The Edge. His website is www.buydonthold.com, where he writes a weekly blog. To submit topics for future columns, reach him at lesmasonson@yahoo.com.
Buy & holders of biotech stocks have been well rewarded over the last 10 years; however, they needed an iron stomach to withstand the big drawdowns during corrections and bear market declines. Any major earnings miss or FDA disapprovals can easily result in a 25% decline or more in the stock price. That is why many investors select a biotech mutual fund or ETF to spread out the risk ...
Share
